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ABSTRACT
Regulating rsmA Expression in Pseudomonas aeruginosa
by
Sean D. Stacey
Pseudomonas aeruginosa, a Gram-negative bacillus, commonly infects immunocompromised
individuals and uses a variety of virulence factors to persist in these hosts. The
posttranscriptional regulator, RsmA, plays a role in the expression of many virulence factors in
P. aeruginosa. RsmA up regulates virulence factors used in colonizing hosts. However,
regulation of rsmA is not well elucidated. Transposon mutagenesis was performed on P.
aeruginosa containing a transcriptional rsmA-lacZ fusion to answer this question. Mutants were
screened via β-galactosidase assay and transposon insertions identified via arbitrary PCR. A
probable MFS transporter, we named mtpX, was one significant transposon mutant identified. A
∆mtpX mutant containing the rsmA-lacZ transcriptional fusion was constructed to confirm our
results. Further analysis of rsmA, looking at RNA and protein levels, revealed varying results in
nonmucoid versus mucoid backgrounds. Phenotypic assays were performed to characterize this
unknown transporter and develop a putative mechanism as to how MtpX affects rsmA
expression.
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CHAPTER 1
INTRODUCTION
Pseudomonas aeruginosa
Pseudomonas aeruginosa is a Gram-negative bacillus capable of colonizing a wide variety
of environments in part because of its ability to metabolize an array of carbon sources (1).
However, in human hosts the bacterium is an opportunistic pathogen. P. aeruginosa most
commonly infects the immunocompromised hosts. Individuals with Human Immunodeficiency
Virus (HIV) infections, severe burns, or cystic fibrosis (CF) are at an increased risk for P.
aeruginosa infection (5,40). Additionally, P. aeruginosa is frequently associated with infections
of the ears, eyes, and the urinary tract (1,10,40). Indeed, P. aeruginosa is capable of infecting
any tissue in the human body owing to the myriad of virulence factors produced by this
bacterium. In addition, P. aeruginosa biofilms are recalcitrant to antibiotic therapy and treatment
of P. aeruginosa infections is difficult.
Virulence Factors
Colonization is a pivotal step for the bacterium in a human host. P. aeruginosa has 2
virulence factors that aid in the motility of the organism, a single polar flagellum and type IV
pili(1,10). A flagellum is a tail-like propeller on the cell. An ATP motor in the inner cell
membrane powers the flagellum. The flagella can be examined in vitro using swimming or
swarming assays on agar plates of various agar concentrations. While flagella are an important
virulence factor, flagella are recognized by the innate immune system. Toll-like receptor
5(TLR5) specifically recognizes the flagellum protein flagellin and stimulates inflammation
(8,10). P. aeruginosa uses the AprA enzyme to evade the immune response by cleaving the
flagellum into units TLR5 cannot bind (2). However, without flagellar motility P. aeruginosa is
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known to be less virulent or attenuated (10).
Type IV pili are also used for motility as well as adhering to epithelial cells inside the host.
These small appendages are composed of multiple proteins that can extend and retract in to the
bacterial cell (14,25). This type of cellular movement is termed twitching. Like flagella, type IV
pili are also recognized by the immune system and can activate the inflammasome, a group of
proteins that produce inflammatory cytokines (23). Pili are important for adeherence to epithelial
cells as well as form biofilm formation and development (29).
P. aeruginosa also possesses the type III secretion system that is important in acute
infections. This virulence factor is a needle-like projection from the bacterium that directly
injects bacterial toxins into the host cells leading to cell death (23). P. aeruginosa uses the type
III secretion system to inject several toxins, like ExoS and ExoT, into the host cell (12). Like
type IV pili, this virulence factor can also activate the host’s inflammasome (23). The type III
secretion system is important in acute infections but plays little or no role in chronic infections
(6).
When an acute infection persists or is left untreated, P. aeruginosa can become a chronic
infection. The change from acute to chronic infection involves a change in the virulence factors
expressed. For example, type IV pili and the type III secretion system are down regulated when
P. aeruginosa begins expressing a type VI secretion system and alginate production increases
(6,29). The type VI secretion apparatus is still not completely understood, but it functions
similarly to the type III secretion system by infecting enzymatic compouds into host cells or
unrelated bacteria (6). The down regulation of virulence factors such as type IV pili and the type
III secretion system may allow P. aeruginosa to persist in the host by preventing its detection
from the immune system.
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A major factor allowing P. aeruginosa to evade the host’s immune system is its ability to
form biofilms. P. aeruginosa secretes exopolysaccharide in both acute and chronic infection
states (13). The biofilm creates a protective barrier around the bacterial growth and inhibits
chemotherapeutic agents from reaching the cell as well as prohibiting phagocytosis by immune
cells (13). The lungs of individuals with cystic fibrosis create thick, sticky mucus, which acts like
a biofilm because of a mutation in the cystic fibrosis transmembrane conductance regulator
protein (7,36). However, when strains of P. aeruginosa are isolated from these individuals, they
begin to make their own biofilm of alginate similar to that found in the CF lung (6). Alginate has
been shown to inhibit the activity of reactive oxygen species and to prevent phagocytosis
(7,13,40). Several regulators of biofilm formation and development have been described (6, 18,
19, 29) One important regulator of biofilm development and virulence factor regulation is RsmA,
a posttranscriptional regulator(4).
RsmA
In P. aeruginosa, RsmA, or regulator of secondary metabolites, is a crucial protein that
regulates many genes including those important for virulence and biofilm formation (4,5). It has
a predicted molecular weight of 6.9 kilodaltons (kDa)(4). RsmA recognizes the sequence GGA
on messenger RNA (mRNA) and binds this sequence (4,19). By binding mRNA, RsmA inhibits
ribosomal attachment and the bound message is not translated (Figure 1). This is a form of direct
negative regulation. By posttranscriptional regulation RsmA is able to regulate multiple genes,
most importantly virulence factors. Previous studies have shown that in PAO1 and PA14, RsmA
regulates virulence factors that initiate colonization like type IV pili, type III secretion system, as
well as iron acquiring compounds by increasing the expression of these genes (4,5). By binding
mRNA to be translated to make proteins that would suppress these genes, RsmA is able to
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increase these acute infection genes’ expression. Conversely, RsmA will also down regulate the
expression of virulence factors that appear in the chronic infection state (4,5). RsmA also shares
homology with the Escherchia coli protein CsrA (4,26).

Figure 1. Diagram of RsmA function

RsmA has 2 known antagonists, the small RNAs, RsmY and RsmZ, homologous to CsrB
and CsrC in E. coli (4). These small RNAs have numerous GGA repeats that can bind more than
one RsmA at a time (4,19). RsmY and/or RsmZ bind to RsmA and prevent RsmA’s regulatory
activity (4,19). These antagonists are the downstream effect of a larger system that is affected by
quorum sensing (QS), one way for cells to respond to environmental stresses (18). The GacA/S
2-component system, a part of QS, positively regulates the small RNAs that in turn suppress
RsmA’s functioning(18).
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Previous work and our own have demonstrated that RsmA expression is maximal in the log
phase of growth (4, Figure 2). mucA22 has a single guanine missing in the antisigma factor gene,
mucA, causing increased alginate production and a mucoid strain phenotype (24). To begin to
better understand the regulation of RsmA in both the wildtype strain of P. aeruginosa, PAO1,
and a strain representing a chronic infection state, mucA22 (Figure 2), Western blot analysis was
performed. The Western Blot analysis shows that RsmA’s presence increases in log phase and
begins to diminish in stationary phase. We also saw that RsmA is present longer and in greater
amounts in PAO1 than mucA22(Figure 2).

Figure 2. RsmA-HA tagged Western Blot Analysis over 12 hours with 10 μg of protein. We
analyzed both the nonmucoid strain PAO1 and the mucoid strain mucA22. A negative of control
of PAO1 without HA-tagged RsmA was used. Samples were taken from a 500 ml broth culture
seeded with 1% of an overnight culture at 0 time point.
These data sparked our interest in studying RsmA in the mucA22 strain. Another question
we wanted to answer was, “What genes are regulating rsmA expression?” Previous microarray
and and transcriptome analysis in PAO1 and PA14 strains (representations of nonmucoid strains)
have better defined the role of RsmA in the cell (4,5).
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Identifying rsmA Regulators
Two orphan sensor histidine kinases, RetS and LadS, are important in controlling the
amount of free RsmA in the bacterial cell (19,27). However, little is known about the regulators
of rsmA. Additionally, no studies have examined the role of RsmA in the mucoid background.
An rsmA-lacZ transcriptional fusion was assayed in the mucA22 strain to begin to
understand the role of RsmA in chronic-infecting strains. This fusion was designed based on a
primer extension of rsmA (Figure 3). This extension showed that there are 2 transcriptional start
sites for rsmA. Both of the promoters for these start sites were included in the fusion. One of the
putative promoters fits the consensus sequence as an AlgU-dependent promoter (33). This is the
promoter that is 130 bp upstream of the translational start site of rsmA. The other sigma factor
regulating the second promoter has yet to be identified.

Figure 3. Primer Extension of rsmA and genomic sequence showing promoters. There are 2 promoters for
rsmA in PAO1. The distal promoter is an AlgU promoter while the second promoter is still unidentified.
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The fusion strain was conjugated with an E. coli strain bearing the pBT20 plasmid that
contains gentamicin resistance (GmR) and a transposon. Gentamicin-resistant colonies were
examined for β-galactosidase activity. X-gal containing plates were used to screen colonies and
those identified as having differential rsmA expression were used in quantitative β-galactosidase
assays and compared to the parent strain.
Confirming Transposon Mutant Results
After identifying several strains exhibiting differential rsmA expression compared to the
parent strain, our next goal was to identify the gene interrupted by the transposon. When the
transposons insert into the genome, they can affect more than one gene if the genes are in the
same operon. This can cause polar effects downstream of the operon, skewing the βgalactosidase assay results, and, therefore, clean knockout mutants of the interrupted genes had
to be constructed.
We make knockout mutants in the nonmucoid background, PAO1, and the mucoid
background, mucA22. These mutants were subject to growth curve analysis in various broths to
look for possible defects. Knockouts were also constructed for 2 CF clinical isolate strains,
FRD1 and 2192, to confirm the results of the mucA22 mutant. The rsmA-lacZ fusion was
inserted into our knockout mutants and β-galactosidase assays were performed to confirm our
transposon mutant results and refute downstream effects of the inserted transposon. Because
transcriptional fusions indirectly monitor gene expression, RNase Protection Assays and Western
Blot analysis were performed to not only confirm our β-galactosidase results but also to examine
RsmA protein levels. This would allow us to determine rsmA regulators and further our
understanding of rsmA regulation.
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Characterizing the Identified rsmA Regulators
Our last aim was to better characterize rsmA regulators identified in our study. In
particular, we focused on mtpX. We conducted several phenotypic assays based on the visual
traits of the knockout mutants as well as determining their cellular appearance via electron
microscopy. As we characterized the phenotype of the knockout mutant, we were able to gain a
better understanding of the gene’s role of rsmA regulation and describe its mechanisms in both
nonmucoid and mucoid backgrounds.
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CHAPTER 2
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Pseudomonas aeruginosa strain PAO1 was used as the wildtype stain and example of a
nonmucoid background. A strain of PAO1 with the defective antisigma factor mucA,
mucA22/PDO300, was used to represent a mucoid background. Two clinical isolates, FRD1 and
2192, isolated from cyctic fibrosis patients, were also used as mucoid strains to demonstrate
clinical relevance. Escherichia coli SM10 and JM109 strains were used for conjugating various
plasmids with P. aeruginosa strains. JM109 strains had to be triparentally mated with E. coli
contain the pR 2013 vector. All strains were grown at 37 C unless otherwise stated. P.
aeruginosa strains were inoculated on Pseudomonas Isolation Agar(PIA) with the possible
addition of antibiotics (Appendix) while E. coli strains were inoculated on Luria-Bertani(LB)
Agar with possible antibiotic variations(Appendix). Fifteen percent Glycerol stocks were made
for storage of each strain with 500μl of sterile LB broth and 500μl of sterile 30% glycerol.
Strains were scraped from a plate with a sterile stick and placed into the stock tube. These stocks
were stored at -80 C. Various plasmids used can be found in the appendix.
Genomic DNA Isolation
For genomic DNA isolation cultures were grown on PIA plates overnight. The cells were
then scraped from the plate with a sterile stick and washed with 1X TNE(Appendix). Cells were
placed in 1.7 ml microcentrifuge tubes then pelleted by centrifugation at 13.2x1000 rpm for 2
minutes. The cells were resuspended in 1.5 ml of 70% ethanol (EtOH) and placed on ice for 15
minutes. Cells were then centrifuged for 5 minutes and EtOH was poured off and the pellet was
left to air dry. Cells were resuspended in 446μl of TEST buffer (Appendix), 30μl of 20mg/ml of
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lysozyme, and 4μl of 10mg/ml RNase A. Cells then were incubated for an hour on ice and then
frozen at -20 C for 15 minutes. The cells were then incubated at 68 C for 10 minutes. ifty- three
μl of 10% SDS(sodium dodecyl sulfate) was added and left at room temperature(RT) for 15
minutes. Then 87μl of 5M NaCl and 69μl of CTAB(Cetyl trimethylammonium bromide)/NaCl
solution was then added, vortexed, and left to sit for 15 minutes. Tubes were then placed in 20 C for 30 minutes. After thawing, Phenol-Chloroform Extraction was performed. We added
650μl of 24:25:1 chloroform:phenol:isoamyl alcohol(C:P:I) was added and vortexed. Tubes were
centrifuged at 13.2x1000 rpm for 10 minutes. The aqueous layer was removed and placed in a
new microcentrifuge tube with 600 μl TE buffer(Appendix) and 600 μl 24:1 chloroform:isoamyl
alcohol(C:I). Tubes were vortexed and the spun at 13.2x1000 rpm for 10 minutes. The aqueous
later was removed again and placed into a new microcentrifuge tube. Salt and nucleic acid was
precipitated with 1 ml of 95% EtOH and put on ice for 15 minutes. Tubes were centrifuged at
13.2x1000 rpm for 10 minutes and EtOH was poured off. One and a half milliliters of 70% EtOH
was then added, mixed, and centrifuged for 10 minutes. The remaining EtOH was poured off and
pellets were left to air dry. After the EtOH had evaporated completely, DNA pellets were
resuspended in 50 μl of double distilled H2O(ddH2 ). DNA extracted was confirmed via
electrophoresis on 1% agarose gel (Appendix) and samples were stored at 4 C.
Transposon Mutagenesis
A transposon mutant library was created by conjugating the pBT20 vector containg the
mariner transposon and GmR with a mucA22 strain contain an rsmA-lacZ fusion (3,34). The E.
coli strain was grown up overnight in 5ml of LB broth with 15 μg/ml of gentamicin while the P.
aeruginosa strain was grown in 5ml of LB broth. After overnight growth, the P. aeruginosa
culture was incubated at 42 C for 2 hours. Both cultures were then centrifuged at 7000 rpm for 5
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minutes and resuspended together in 500 μl of 0.85% NaCl. The mixed strains were then
vortexed and dispensed into the middle of a LB plate for 1.5 hours at 30 C. The plate was then
scraped and the cells were again resuspended in 500 μl of 0.85% NaCl. These cells were then
spread-plated over four 150 μg/ml gentamicin PIA plates and incubated at 37 C overnight.
Gentamicin-resistant colonies appeared 1 to 2 days after incubation at 37oC.
Patch Plating
Individual colonies were picked from the PIA gentamicin plates with a sterile toothpick
and patch-plated on to a 80 μg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside( -gal)
PIA gentamicin plate. There were 52 colonies patched per plate. These plates were then
incubated at 37 C overnight. A blue color was evident from the mucA22 strain carrying the
rsmA-lacZ fusion after 24 hours. This strain was used to compare the transposon mutant library.
Transposon mutant patches with lighter or darker blue appearance compared to the parent strain
were then further analyzed.
β-Galactosidase Assay
Transposon mutants identified in the patch plate assay for differential rsmA expression
were tested in a quantitative β-galactosidase assay (28). Strains were grown overnight on
gentamicin PIA plates or mucA22 rsmA-lacZ on PIA plates or in 16 hour LB broth culture
(gentamicin added for transposon mutants to 20μg/ml). Pellets of cultures were collected either
with 1ml of 1 TNE and scraping from a plate or 350 μl of broth culture and centrifuged. Cells
were resuspended in 1 ml of Z Buffer (Appendix) and optical density (O.D.) 600nm was
measured. Samples needed to be between 0.4 – 1.0. ifty μl of 0.1% SDS and 100 μl of
chloroform were then added to each sample and vortexed for 15 seconds. Samples were left to
set for 10 minutes. One hundred microliters of supernatant was removed and placed in a new
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microcentrifuge tube with 800 μl of Z buffer. 200 μl of ortho-Nitrophenyl-β-galactoside(ONPG)
solution (4 mg/ml ONPG in Z buffer) was added to each sample and reaction time was recorded
until samples turned a yellow color. At the time point of yellow color, 500 μl of 1M Na2CO3 was
added to stop the reaction. O.D. 420nm and 550nm was then recorded. Values were then
substituted into the Miller Units.
Equation:
1000 x (O.D.420nm -1.75x O.D. 550nm) =
Time x Volume of sample x O. D. 600nm

Miller units of
β-galactosidase activity

Arbitrary PCR
Transposon mutants having differential β-galactosidase activity were then subject to
arbitrary PCR to amplify flanking regions of the mutant chromosome adjacent to the transposon
(30). Taq DNA polymerase and Thermopol Buffer were purchased from New England Biolabs
(NEB). A revised version of the George ’Toole and olter protocol is as follows (Table 1).
Perform genomic DNA isolation on mutant and digest with either EcoR1 or BamH1 restriction
enzyme.
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The PCR#1 product in Table 2 is simply 1.5 μl of the 50 μl volume without clean up or gel
extraction. Products of PCR#2 were run on a 1.5-2% agarose gel to confirm amplification then
cleaned up via Promega Wizard® SV Gel and PCR Clean-Up System. Samples were then sent to
the ETSU Molecular Biology Core for sequencing.
Mutant Construction
To confirm transposon mutant results knockout mutants were constructed. This was
performed so that any polar effects due to transposon insertion in the mutant library were
nullified.
Splicing by Overlap Extension
Two sets of primers, F1 & R2 and R1 & F2, (Appendix) were designed around the gene of
interest (17). F1 is at a region 1000 bases upstream from the gene while R1 is 1000 bases
downstream. The F1 and R1 primers both have 4 random nucleotides at their 5’ end and then an
endonuclease site of choice. The endonuclease chosen usually is found in not only a cloning
vector but a suicide vector as well and cannot cut the sequence being amplified. F2 and R2 are
slightly more complex. R2 is on the bottom strand under the translational start of the gene
usually between an 18 to 20-mer. This sequence is then reverse complemented and starts the 5’
piece of the F2 primer. F2 is on the top strand including the translational stop of the gene and this
18 to 20-mer is also reverse complemented and starts the 5’ of the R2 primer. These reverse
complements will create overhangs on the first fragments that will aid in annealing the segments
together in the second PCR. A 1000 base pair (bp) fragment was amplified upstream(5’ segment)
and downstream(3’ segment) of the gene. In a second PCR, both of these fragments were spliced
together via regions of homology on the F2 & R2 primers and then amplified to
create a knockout construct. The 1 & R1 primers also had restriction enzyme sites on the 5’ end
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so that ligating with a suicide vector, pEX18Tc, would be easier. After each PCR the amplified
segment was gel extracted and put through the Promega Wizard® SV Gel and Clean- Up
System. This clean up system removes any debris from the agarose gel and purifies our amplified
segments.
Plasmid DNA Isolation
Cultures were grown overnight with appropriate antibiotics in 5ml of LB broth. On the
second day the culture was spun down in a centrifuge at 7000 rpm for 10 minutes. The LB broth
was poured off and the pellet was resuspended in 150 μl TE. This suspension was transferred to a
microcentrifuge tube and 300 μl of 1% SDS/ 0.2M Na H was added and mixed. The tube was
incubated on ice for 5 minutes. 225 μl of potassium acetate/acetic acid (5M potassium acetate
and 11.5% acetic acid) was then added along with 4μl of 10mg/ml RNase A, mixed, and then
incubated on ice for 5 minutes. The tubes were then centrifuged at maximum speed for 10
minutes in a microcentrifuge and the supernatant transferred to a new tube. Phenol-ChloroformIsoamyl alcohol was added in equal volume, vortexed, and centrifuged for 5 minutes. The
aqueous phase was removed to a new tube and the plasmid DNA precipitated using 95% EtOH
and incubation on ice for 10 minutes. The plasmid DNA pellet was washed with 70% EtOH, the
pellet air dried, and the plasmid DNA was resuspended in 50 μl of ddH2 and stored at -20 or
4 C.
Double Digest & Ligation
Both the knockout construct and suicide vector were individually double digested with the
necessary restriction enzymes to produce sticky ends on both products (Table 3).
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If possible, restriction enzymes were inactivated using heat inactivation or using Promega
enzymatic cleanup protocol. After double digest was performed, a new microcentrifuge tube was
used for the ligation with a 1:3 molar ratio of plasmid to knockout construct. The molar amount
of a DNA sample can be calculated by quantifying it using the spectrophotometer at A260.
Calculating the μg/ml by multiplying the value from A260 * 50 * 100. Then dividing this
amount by 0.66*size of DNA segment. 0.66 is the average weight of 1 base pair of nucleotides
(38). ddH2O, T4 DNA ligase buffer, and T4 DNA ligase were added to the tube and put at 4 C
overnight (Table 4). To confirm the ligation

was successful, 3 μl of the volume was removed before adding the T4 DNA ligase and run on a
1% agarose gel with 3 μl of the post ligation volume. The preligation lane should contain 2
bands, the insert and the plasmid, while the postligation lane can contain a smear and no insert
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band.
Transformation
After ligation, 100-150 μl of competent E. coli SM10 or M109 cells were placed on ice
and 5 μl of the post ligation mix was added and incubated for 10 minutes. This mixture was
placed at 42 C for 45 seconds to 1 minute and then placed on ice for 2 minutes. One milliliter of
LB broth was added to the microcentrifuge tube and placed on a shaker at 37 C for 1 hour to
rescue. The cells were pelleted and spread-plated on to an LB plate with the appropriate
antibiotic for the suicide vector to be expressed as a form of positive selection. Colonies were
screened using blue-white selection. White colonies were grown up overnight in LB with the
appropriate antibiotic and plasmid DNA isolated and digested with the appropriate restriction
enzymes to confirm insertion of the amplified construct into the suicide vector.. The final suicide
construct was verified by sequencing at the ETSU Molecular Biology Core facility.
Homologous Recombination
In order to perform allelic exchange, the suicide construct was conjugated into various P.
aeruginosa srains using tri-parental or bi-parental mating. Merodiploid colonies were obtained
by selecting for antibiotic resistant colonies postconjugation indicating that the suicide construct
had inserted into the bacterial chromosome. Merodiploids placed in 5 ml of LB broth overnight
without selection in order to allow for a second cross-over event. Due to counter-selectable
marker sacB, gene on the suicide vector, coding for the protein levansucrase, sucrose counterselection was used to detect bacteria that had undergone the second recombination event. Serial
dilutions of 10-4, 10-6, and 10-7 were performed on LB 10% Sucrose plates. Sucrose-resistant
colonies were patch plated onto antibiotic plates and PIA plates. Bacteria only growing on PIA
were screened via internal primers to detect wildtype or mutant variation.
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Growth Curve
Cultures of P. aeruginosa were initiated in a 5 ml LB broth overnight. On day 2, the
absorbency at O.D. 600nm was measured and diluted to 0.1. A 99 ml broth, either LB or minimal
media, was seeded with 1 ml of the diluted culture. O.D. 600nm reading was taken every 3
hours. The experiment was performed in triplicate. Minimal media consisted of M9 salts
(Appendix) and either 1% glucose or 1% succinate as a carbon source.
Construction of rsmA-lacZ Transcriptional Fusion Strains
Mutant strains were conjugated, in the same fashion as the suicide vector in the mutant
construct section, with the mini-CTX-lacZ plasmid containing the rsmA-lacZ fusion (39). miniCTX-lacZ uses the attB site on the P. aeruginosa chromosome for insertion. By doing so, it is
inserted as a single copy, unlike other complementation vectors that have multiple copies in the
cell. Colonies with tetR were than grown up overnight and conjugated with an E. coli strain
containing the plasmid pFLP2 to flip out the mini-CTX plasmid vector backbone and leave the
rsmA-lacZ fusion. This conjugation was then streaked for isolation on VBMM Carb300 plates
(Appendix). The isolated colonies were patch plated on to LB tet irg (Appendix) and PIA plates
to confirm the loss of the tetR gene. Growth overnight at 37°C without selection was used to cure
the P. aeruginosa strains of pFLP2. Colonies grown on PIA and killed on VBMM Carb300 were
then screened for the rsmA-lacZ insert via rsmA forward and lacZ reverse primers (Appendix).
RNA Isolation
Cultures of P. aeruginosa were grown in 5 ml of LB broth for 6 to 8 hours (37). Three
hundred microliters of the culture was aliquoted into a microcentrifuge tube and pelleted at 7000
rpm for 5 minutes. LB broth was poured off and 1 ml of TRIzol® (Invitrogen) was used to
resuspend the pellet. Five hundred μl of glass beads were added and beat for 3 intervals at 20
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seconds. Tubes were intermittently placed on ice. Tubes were left to set for 10 minutes. The
TRIzol®/cellular mix was then removed and added to a clean microcentrifuge tube with 200μl of
chloroform. Tubes were inverted for 2 minutes and then centrifuged for 10 minutes. Supernatant
was then added to the column of the Promega SV Total RNA Isolation System. The Promega SV
Total RNA Isolation System protocol was then followed. After 2 elutions, 20μl of sodium acetate
was added and 500μl of 95% Et H was followed. Tubes were incubated at -20 C for 15 minutes.
Tubes were then centrifuged for 10 minutes and EtOH was poured off. 1 ml of 70% Et H was
placed on top of the RNA/salt pellet and tubes were stored at -80 C until used. All reagents used
DEP-C treated or nuclease free water. Successful RNA isolation was confirmed via
electrophoresis with an 1% agarose/formaldehyde gel(). Quantifying RNA was done with 5 μl of
RNA sample in 495 μl of TE. Absorbance was measured at .D. 260 and 280. Purity was
confirmed by the ratio A260/A280, while amounts were estimated by multiplying A260 x
40(representative of weight) x 100 (dilution factor).
RNAse Protection Assay
The RPA IIITM Ribonuclease Protection Assay Kit (Ambion®) was used for this assay.
The protocol with this kit was followed and used to design and make a biotinylated probe for
rsmA mRNA. The rsmA probe is a single strand of antisense RNA to the mRNA of interest, in
this case rsmA’s mRNA. The probe was made via primers (Appendix) for rsmA with a reverse
primer also containing a promoter for T7 phage RNA polymerase (Ambion RPAIII Kit). The
sequence was transcribed via the RNA polymerase and then gel extracted from an 8M urea/
5%acrylamide gel (Table 5). The probe was aliquoted and stored at -20oC. After aliqoting the
probe, the 5 μg of RNA samples and a negative control of yeast RNA were added to a clean
microcentrifuge tube and 3 μl of a 200-fold diluted probe were hybridized with hybridization
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buffer over night at 42°C. A solution of RNase Digestion Buffer 3 and RNase A/T1 was made
with 150μl Digestion Buffer 3:1μ RNase per tube. The RNase was not added to the probe by
itself. These samples were then incubated for 30 minutes at 37°C. After, 225μl of Inactivation
Solution was added and the samples were incubated at -20°C for 15 minutes. The tubes were
centrifuged for 15 minutes at maximum speed. The supernatant was removed and 10 μl of
loading buffer was added. The samples were heated at 92°C for 5 minutes and then placed in
slushy ice. Samples of RNA and probe were run on a 5% acrylamide / 8M urea gel (Table 5) and
run

in 1X TBE buffer (Appendix) at 200 V. The gel was electroblotted in 0.5X TBE for 1 hour at
150 mA on to a nitrocellulose membrane. The membrane was then UV crosslinked for 30
seconds. The BrightStar® BioDetectTM Kit (Ambion®) was then used detect protected RNA
samples on the membrane. The kit’s protocol was followed. To visualize the samples a
ProteinSimple FluorChem M system was used with the chemiluminescence option.
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Insertion of rsmA-HA Tag
The suicide vector pEX18Gm was used to clone the rsmA gene with hemaglutinin(HA) tag
added to the 3’ end of the rsmA gene. This vector was conjugated as described previously into
various P. aeruginosa strains. Primers rsmA SDM check F(forward) and rsmA R check(reverse)
were used to detect the addition of the HA portion on to rsmA (Appendix).
Western Blot Analysis
Cultures of P. aeruginosa were either grown in LB broth or harvested from LB plates after
12 hours. Cells were pelleted in 2 ml tubes and resuspended in 0.85% NaCl to a final volume of
1.7 ml. Tubes were left on ice. Thirty microliters of 20mg/ml of lysozyme was added to help lyse
of the cells. Sonication was performed for each tube for 20 seconds twice. Intermittently, tubes
were left on ice between sonication. Tubes were centrifuged at 7000 rpm for 10 minutes to pellet
debris. Supernatant was removed and placed into a new microcentrifuge tube. A standard curve
was created using the Bio-Rad Protein Assay and BSA at concentrations of 0.0625 mg/ml, 0.125
mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml, and 2.0 mg/ml. Ten milliliters of colorimetric assay
dye was added to 40 ml of ddH2O. Thirty microliters of each BSA sample was added to 3.5 ml of
the assay dye solution. Thirty microliters of each HA-tagged sample’s supernatant was also
added to 3.5 ml of assay dye solution to quantify the amounts of protein against the standard
curve. All samples were measured at O.D. 595nm. The BSA samples were then analyzed in
Excel and a standard curve generated. The amount of protein in the cellular samples was
calculated from the trend line equation. Only R2 values of 0.98 or higher were used. Ten
micrograms of cellular samples were mixed with a 4 SDS PAGE loading dye (Appendix). The
samples were heated for 5 minutes at 92 C, briefly centrifuged, and put in slushy ice. A
discontinuous SDS-PAGE gel of 4% stacking/15% separating (Table 6) was used for the RsmA-
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HA Western Blot. Samples were run at 180 V until the dye front

reached the end of the separating gel. The gel was run in 500 ml of 1X Glycine Running Buffer
(Appendix). To prepare for transferring to a polyvinylidene fluoride (PVDF) membrane, 1X
Towbin Buffer (Appendix) and 10%methanol were used for transfer to the PVDF membrane
after soaking in methanol for 10 minutes The transfer apparatus was assembled and run at 150
mA for 1.5 hours.
After transferring, the membrane was removed from the sandwich and placed in Blocking
Buffer (Appendix). This was rocked for 2 hours at RT. The Blocking Buffer was poured off and
1 antibody for HA was added (Appendix) at a 1:10,000 dilution. This was rocked at 4 C
overnight. On day 2, the antibody wash was poured off and washed 3 times with Washing Buffer
(Appendix) for 15 minutes each time. The 2 antibody (goat anti-mouse) containing conjugated
horseradish peroxidase was added (Appendix) at a 1:10,000 dilution for 1 hour and rocked at RT.
The antibody wash was poured off and washed again 3 times for 15 minutes each time. Lastly,
the Pierce ECL Western Blotting Substrate kit was used to visualize the proteins tagged on the
membrane. 3 ml of Substrate A and 75 μl of Substrate B were mixed and poured over the
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membrane. The membrane was hand rocked for 5 minutes. The membrane was then transferred
to the ProteinSimple FluorChem M visualizer for data analysis.
Swimming Assay
LB plates (0.3% agar) were used in this experiment (22). Cultures of P. aeruginosa were
grown up overnight and transferred to swimming plates via a sterile toothpick. Plates were
stabbed with the inoculated sterile toothpick and incubated at 30 C for 48 hours. The zone of
growth was measured in centimeters. Experiments were performed in triplicate.
Twitching Assay
LB plates (1.5% agar) were used in this experiment (22). Cultures of P. aeruginosa were
grown up overnight and transferred to twitching plates via a sterile toothpick. Plates were
stabbed with the inoculated sterile toothpick and incubated at 30 C for 48 hours. Agar was
removed with a sterile stick and 1% crystal violet was used to flood the plate and left to set for 5
minutes. This stain was used to visualize the twitching zones. The crystal violet was washed with
water and twitching zones were measured in mm. Experiments were performed in triplicate.
Transmission Electron Microscopy (TEM)
Cultures were streaked for isolation and grown up on PIA plates overnight. 5 μl of ddH2O
was added to a Formvar/Carbon film coated, 200 Mesh, Cu, TEM grid. To this drop of water, a
single colony was picked with a sterile toothpick and touched for 5 minutes to the water(14).
ive μl of 1% uranyl acetate (UA) was added to the drop of water and left to set for 45 seconds.
The drop was then wicked with sterile chromatography paper from the other side of the grid
where the drop was placed. Grids were stored in a carrier and taken to the TEM facility.
Microscopy was performed with a Philips Tecnai 10 transmission electron microscope with an
acceleration of 80 kV.
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Iron Acquisition on Chrome Azurol S Plates
Chrome Azurol S(CAS) plates were used to study the degree of iron acquisition of
wildtype versus mutant strains (21). Iron III solution consisted of 27 mg FeCl3 •6H2 , 83.3 μl of
12M HCl, and 100 ml ddH2O. Basal Agar Medium consisted of 415 ml ddH2O, 15g of 3-(Nmorpholino)propanesulfonic acid (MOPS), 0.25 g NaCl, 0.15g KH2PO4, 0.05g NH4Cl, 2.5g of Lasaparagine. The pH of solution was measured to 6.8 with 5M NaOH and 7.5g of agar was added
and then autoclaved. CAS indicator solution consisted of: Solution A, 60.5mg Chrome azurol S
and 50ml of ddH2O, after dissolving, 10ml of Iron III solution was added, Solution B, 72.9mg
hexadecyltrimethyl ammonium bromide (HDTMA) and 40ml of ddH2O. Solution B was slowly
added to Solution A and autoclaved. After autoclaving and allowing the basal agar medium to
cool, 10ml of 50% succinate and 50ml of the CAS indicator solution were added and mixed.
Cultures of P. aeruginosa were grown overnight and transferred to CAS plates via a sterile
toothpick. Plates were stabbed with the inoculated sterile toothpick and incubated at 30 C for 48
hours.
Biofilm Assay
The microtiter dish biofilm formation assay described by ’Toole was performed on
wildtype and ΔmtpX mutants as well as Congo Red media (22,31). LB broth cultures were grown
overnight and the next day diluted 1:100 in M63 broth (Appendix). One hundred microliters of
the dilution was added to a row of wells on a 96-well flat bottom plate. The dish was incubated
for 24 hours at 37 C. Plates were washed 2 times with ddH2 and then 125 μl of 1% CV was
added to each well and set for 10 minutes. The plate was washed 3 times with ddH2O to remove
excess CV and left to dry overnight. 125 μl of 33% acetic acid was added to each well to
solubilize the CV. The plate was then read in a microtiter plate reader at O.D. 620nm. This
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experiment was performed in triplicate.
Alginate Assay
Pseudomonas cultures were grown on PIA plates at 37 C for 48 hours. Plates were scraped
with a sterile stick and contents added to 0.85% NaCl. Cells were centrifuged to separate alginate
from the cell. Supernatant was removed and stored in a separate tube. Three milliliters of
Sulfuric Acid/borate solution (Appendix) was transferred to glass tubes on ice and 350 μl of the
supernatant was layered on top. A standard curve was made from alginic acid in amounts of: 5,
50, 100, 200, 300, 600, and 1000 μg/ml. Tubes were vortexed for 1 second and put back on ice.
One hundred microliters of 0.1% Carbazole in Et H was added and vortexed. Tubes were then
placed in a 55 C water bath for 30 minutes (20). Tubes were removed and allowed to set at RT
for 5 minutes. Absorbency was measured at O.D. 530nm. This experiment was performed in
triplicate.
Reverse Transcriptase PCR(RTPCR)
The GoScriptTM Reverse Transcription System by Promega was used to produce cDNA.
Both random primer (data not shown) and specific primer were used to generate cDNA. Isolated
RNA from PA 1 was quantified and 5μg was used. The RNA, 1 pmol of primer, nuclease free
water to a volume of 5 μl were added to a PCR tube. This tube was incubated at 70°C for 5
minutes and then placed on ice. The tube was incubated at RT for 5 minutes with the addition of
4 μl of GoScriptTM 5 Reaction Buffer, 2 μl of MgCl2, 1 μl of PCR Nucleotide Mix, 20 units of
Recombinant RNasin® Ribonuclease Inhibitor, 1 μl of GoScriptTM Reverse Transcriptase, and
1.5 μl Nuclease-Free water. The extension step was incubated at 42°C for 1 hour. The Reverse
Transcriptase was incubated at 70°C for 15 minutes to inactivate the enzyme. cDNA samples
were incubated at -20°C until time for PCR. A negative control was also performed without
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Reverse Transcriptase. The PCR that followed had a shorter series of cycle repeats, 26, versus
the PCR used to generate the genomic DNA control with 30 cycle repeats. Results were run on a
1% agarose gel and performed in triplicate with 2 different RNA preps.
Statistical Analyses
Where applicable, experiments performed in triplicate were subject to mean, standard
deviation, and standard error analysis. Graphs show means and standard error via error bars.
Student’s t test was also performed to confirm significance within each experiment. Stars show
statistical significance with 1 star having a p<0.05 and 2 stars having a p<0.01.
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CHAPTER 3
RESULTS
Transposon Mutant Screen
By using the rsmA-lacZ transcriptional fusion designed from the primer extension data
(Figure 2), we looked at rsmA expression in the mucoid strain, mucA22, versus the wildtype
strain PAO1(Figure 4). After seeing a significant increase in rsmA expression, we set out to
identify possible regulators of rsmA causing this significant increase in expression. To identify
regulators of rsmA,

Figure 4. rsmA expression is increased in a mucA22. PAO1 and the isogenic strain mucA22 were
both analyzed via β-galactosidase assay with the transcriptional fusion rsmA-lacZ.
we created a transposon mutant library with the parent strain mucA22 rsmA-lacZ and the
transposon vector pBT20 (Figure 5).
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Figure 5. A representation shows conjugation between transposon vector with GmR gene and
mucA22 rsmA-lacZ to visualize the creation of transposon mutants.
Patch Plating
Transposon mutants were picked from PIA gentamicin plates with a sterile toothpick. Only
colonies that were isolated as a single colony were chosen to avoid contamination. Growing
colonies on PIA gentamicin plates ensured that there would be no E. coli due to irgasan and no
parent mucA22 rsmA-lacZ without the transposon and GmR genes. X-gal was added to visualize
differences in rsmA expression levels. Because it can take up to 48 hours for alginate to
accumulate from the patched colony, plates were observed over the course of 2 days to look for a
mucoidy appearance. In terms of β-galactosidase activity on the plates, after incubating
overnight, the plates were left at room temperature for an hour to let blue color develop further
(Figure 6). The patched mutants were compared to a patched colony of mucA22 rsmA-lacZ.
Those colonies that were drastically darker or lighter than the parent strain with the
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transcriptional fusion were then streaked for isolation on PIA gentamicin plates. The plates were
incubated overnight. Freezer stocks were made for storage of the transposon mutants of interest
and those mutants were also subject to β-galactosidase assay.

igure 6. Patched transposon mutants on a PIA 80 μg/ml -gal 150 μg/ml gentamicin plate. The
blue pigment is a result of rsmA expression from the rsmA-lacZ transcriptional fustion.
β-Galactosidase Assay
Over 50 transposon mutants have been screened via the β-galactosidase assay since the
start of our project looking for regulators of rsmA. The assay was performed with 16-hour
cultures. The mutants that we analyzed were performed in triplicate to assure that the assay was
consistent. We also compared results of broth versus cultures grown on a plate to look for
variances in rsmA expression between the 2 environments. Student’s t test was performed on the
values of the individual transposon mutants and mucA22 rsmA-lacZ to look for significant
differences between the 2 (Figure 7). If the p value was less than 0.05, we considered it a
significant difference to further study the transposon mutant by identifying the interrupted gene.
We have identified 50 signficiant mutants by this method, 20 of which have exhibited very
significant differences. The most drastic difference we have seen is a fourfold decrease in rsmA
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expression. Some mutants were identified by arbitrary PCR for their interesting appearance or
odd growth patterns on plate medium.

Figure 7. β-Galactosidase Assay results with t test analysis. This experiment was performed in
triplicate to ensure the least amount of error. mucA22 rsmA-lacZ was our standard we compared
the transposon mutants to in this experiment. One star signifies p<0.05 and 2 stars signify
p<0.01.
Arbitrary PCR
The original arbitrary PCR protocol called for adding all 3 primers to amplify the
transposon interrupted region (30). However, we found that we had more success using the
arbitrary primers individually instead of used together as the protocol suggests. We also
discovered that Arb1 and Arb2 primers were more successful at amplifying segments to be
sequenced than Arb3. Samples were sent to the ETSU Molecular Biology Core to be sequenced.
We used the program Chrome to analyze the results and then BLAST the sequence on
http://www.pseudomonas.com to identify which gene was interrupted (41). Based on our βgalactosidase assay, Table 7 lists 9 genes that have been identified to regulate rsmA expression in
P. aeruginosa, one previously identified in another study. pilW was the first to be identified in
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this experiment. An individual project revolving around the minor pilin gene was begun at that
time, but we continued to identify genes. Another important gene identified by arbitrary PCR
was retS. RetS is a negative regulator of the GacA/S 2 component system, which in turn favors
production of RsmA (27).

PA1626 is another gene of interest from this study, which we named mtpX. Our βgalactosidase assay showed a 4-fold decrease when compared to mucA22 rsmA-lacZ. Other
mutants ranged from a two-thirds increase (dsbA) to almost fivefold decrease (PA1192) in terms
of Miller units measuring rsmA expression. The mucoid strain became nonmucoid as well as had
very decreased levels of rsmA expression via the lacZ reporter. After identifying this gene via
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sequencing, we set out to make a knockout of mtpX in order to confirm our results from the
transposon insertion. Like pilW, mtpX was in an operon, but it is located next to a transcriptional
regulator. This transposon insertion could have complicated our results by interrupting the
message of both genes. We then began to make a knockout mutant of mtpX.
Mutant Construct
Two genes, pilW and mtpX, were selected for making mutants to compare results with the
transposon mutants. Primers were designed to amplify segments surrounding the gene of interest
(Figure 8). These segments were then spliced together to create the deletion construct.

Figure 8A. Diagram showing Construction of mutant strains
The individual 5’ and 3’ fragments were successfully amplified as a single amplicon of
approximately 1000bp and were gel purified without UV exposure as well as ethidium bromide
that might have damaged DNA. The 5’ and 3’ pieces were successfully used as templates in a
second PCR using primers, F1 and R1 (Figure 8B).
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igure 8B. 1% agarose gel used to show amplified 5’ and 3’ segments along with S E amplified
segment. MW is molecular weight marker used to measure amplified segments of DNA.
This mutation construct was digested along with both a cloning vector and suicide vector.
We used a cloning vector as a precaution in case more knockout constructs were required. The
mutant construct was then ligated into the suicide vector and then transformed in E. coli. The
mutant construct was conjugated into various P. aeruginosa strains. After making merodiploids,
which are cells with both mutant and wildtype genes, we left them to perform homologous
recombination in LB broth overnight. This broth was serially diluted on 10% sucrose LB plates.
The second crossover was successful as determined by detection of the mutant allele on sucroseresistant colonies after PCR analys using primers (Appendix). After completing the mutant
screening successfully and confirming the mutation with internal detection primers, freezer
stocks were made of the mutants. We made mutants in both mucoid and nonmucoid
backgrounds.
Growth Curves of ΔmtpX Mutants
One possible explanation for the differential rsmA expression in the transposon mutants is
that these mutants have a growth defect due to the transposon insertion. To address this
possibility, we performed growth curve analysis of the constructed mtants compared to the wild
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type strains. As the mtpX mutant may have a arole in supplying nutrients to the cell, we analyzed
the growth kinetics of this strain in several media, both complex and minimal media.
In LB Media
In LB broth, there was no difference between the mutants and the parent strains. PAO1 had
a spike in the O.D. reading at 12 hours, but overall there was no difference. This growth curve
analysis was performed in triplicate to ensure that there was no difference between growth of the
mutants and PAO1 or mucA22. These results can be seen in Figure 9. In addition our results
demonstrate that in complex media there is both the nonmucoid PAO1 and the mucoid strain,
mucA22, have similar growth kinetics.

Figure 9. Growth Curve analysis of mtpX mutants versus PAO1 and mucA22 show no variation
in growth. PA 1(blue diamond), PA 1∆mtpX(red square), mucA22(green triangle), and
mucA22∆mtpX(purple X) were grown in LB broth over 24 hours. Standard error bars are shown
at each time point.
In Minimal Media
Because MtpX may play a role in the metabolism of P. aeruginosa, we compare the
growth of the mtpX mutant to the parent strain in minimal media using different carbon sources.
M9 salts minimal media and an added carbon source; either glucose or succinate was used.
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1% Glucose. P. aeruginosa does not readily metabolize sugars like glucose, sucrose, and
lactose (9). However, it can still grow using glucose as the sole carbon source. There again was
no difference in growth between the mutants and parent strains (Figure 10). However, there was
a visual difference in growth. Around the 12 hour time point, PA 1, PA 1∆mtpX, and
mucA22∆mtpX, all changed color of their media to a red pigment, which we predict is secreted
pyorubin, while mucA22 remained yellow in color. It is interesting to note the difference in the
mucA22∆mtpX. This mutant was able to secrete pyorubin with the inner membrane protein MtpX
removed from the cell in the mucoid background.

Figure 10. Growth Curve Analysis in 1% Glucose minimal media shows no variations between
mutants and parent strains. PA 1(blue diamond), PA 1∆mtpX(red square), mucA22(green
triangle), and mucA22∆mtpX(purple X) were grown in minimal media broth over 24 hours.
Measurements were recorded at O.D. 600nm.
1% Succinate. Succinate is readily metabolized by P. aeruginosa. This carbon source also
increased pyoverdine secretion. There was no difference in growth analysis (Figure 11). The
strains also exhibited pigment change at the same time.
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Figure 11. Growth Curve Analysis in 1% Succinate minimal media shows no variations between
mutants and parent strains. PA 1(blue diamond), PA 1∆mtpX(red square), mucA22(green
triangle), and mucA22∆mtpX(purple X) were grown in minimal media broth over 24 hours.
Measurements were recorded at O.D. 600nm.
β-Galactosidase Assay of ΔmtpX Mutants with rsmA-lacZ Fusion
In order to confirm our transposon mutant results from the β-galactosidase assay, we
inserted the rsmA-lacZ fusion into the knockout mutant’s chromosome of both backgrounds.
These were performed from broth cultures and done in triplicate (Figure 12) with t tests to show
significance. We not only repeated our transposon mutant results in this knockout mutant but
also showed a significant decrease in the nonmucoid background strain PAO1. This confirms the
transposon screen results and suggests that MtpX affects rsmA expression by some undefined
mechanism.
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igure 12. Β-galactosidase assay shows significant decreases in ΔmtpX mutants’ rsmA
expression. Miller units were calculated from recording O.D. 600nm, 420nm, and 550nm during
the course of the assay using Miller’s equation. ne star represents a p<0.05 and two stars, a
p<0.01.
RNase Protection Assay of ΔmtpX Mutants with rsmA Probe
As transcriptional fusion analysis is one way to analyze gene expression, it uses a reporter
gene controlled by the promoter of the gene of interest. This provides an indirect measurement of
gene expression. In order to directly measure the amount of rsmA message, we performed an
RNase protection assay. A probe consisting of biotinylated rsmA antisense message was
produced by invitro transcription, gel purified, and used in a hybridization experiment using total
RNA isolated from various strains. The RNA probe was combined with RNA isolated from each
of the 4 strains (Figure 13). RNA was isolated at 6 to 8 hours from broth cultures, so there is
potential for change in results when compared to rsmA expression using a transcriptional fusion
measured at 16 hours. However, when comparing PAO1 and mucA22 we see darker bands in the
mucoid background versus the nonmucoid. The protein simple Fluoro Chem M imager was used
to confirm analysis of the intensity of the bands present (data not shown).
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Figure 13. RNase Protection Assay with ΔmtpX mutants. These results show that the nonmucoid
mutant is actually increasing rsmA expression via the AlgU promoter while the mucoid
background mutant has less expression than that of mucA22. A negative control was used with
yeast RNA and the rsmA probe. The top arrow marks the band transcribed from the AlgU
promoter while the lower arrow shows the unknown promoter.
We see 2 bands as well, which indicates that there are 2 rsmA messages. This result is
supported by the primer extension results demonstrating that there are 2 transcriptional start sites
(Figure 3). The longer message is from the AlgU-dependent promoter while the lower band is
controlled by an unknown sigma factor.
These results vary from the β-galactosidase assay, which showed decrease in rsmA
expression in the nonmucoid mutant. The only variable here is time of experiment. We showed
(Figure 2) that RsmA is diminished greatly between 6 hours and 12 hours in PAO1 and this may
explain our RNase protection assay results. Two bands can be seen in the 2 parent backgrounds,
PAO1, and mucA22. The messages appear more intense in the mucoid background supporting
our β-galactosidase assays. However, the mtpX mutant has a great deal more message from the
AlgU-dependent promoter and a very faint band representing the second message. This result
suggests that there is more rsmA message from the AlgU promoter and this may be due to
different RNA concentrations or different levels of RNA degradation.
In the mucoid background, we confirm our β-galactosidase results. The top band in the lane
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with the mucA22ΔmtpX is slightly lighter in appearance when compared to mucA22. The second
band, however, is significantly lighter than that of mucA22. The correlation between both these
messages has not been elucidated and how much they effect the β-galactosidase results is
unclear. Another time course experiment using the RNAse protection assay may be useful in
seeing the expression of the various messages in both mucoid and nonmucoid background. We
also have a construct consisting of a site-directed mutation of the AlgU promoter of rsmA and
would like to repeat this experiment to confirm that these results are consistent with our primer
extension data showing the presence of 2 messages as well to prove the results of the PAO1
mtpX mutant.
Western Blot Analysis of ΔmtpX Mutants with HA Tagged RsmA
An alternative way to look at rsmA expression is to determine the levels of RsmA in the
cells. We confirmed the presence of the HA tag via PCR and running the amplified products on a
1% agarose gel. The mtpX mutants were made by conjugating the ΔmtpX construct with PAO1
and mucA22 strains with the HA-tagged RsmA already inserted on the chromosome. Using an
HA- tagged RsmA, we were able to analyze the abundance of RsmA in the various strains. These
cultures were taken from LB plates to reduce the amount of alginate produced by mucA22. The
strains were grown for 12 hours, lysed, and 12 μg of protein was loaded into each well. We saw a
very different result in our Western Blot (Figure 14). PAO1 showed more RsmA present than
that of mucA22. This is
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igure 14. Western Blot of ΔmtpX mutants with HA-tagged RsmA. 20μg of protein was used.
PAO1 without HA-tagged RsmA was used as a negative control. The arrow marks the HAtagged RsmA and its size of approximately 7 kDa. When 20 μg of protein is loaded,
PA 1∆mtpX appears to have more HA-tagged RsmA(data not shown).
contrary to our β-galactosidase and RNAse protection assays. The nonmucoid background does
not seem to be affected by the removal of mtpX; however this may be because 20 μg were loaded
on the SDS-PAGE. For the mucoid background, we see the same decrease in the mtpX mutant as
reported before in other assays. This experiment was repeated twice to confirm the results
because there was no presence of RsmA detected in the mucA22ΔmtpX strain.
Motility Assays
Having patched the mtpX mutants multiple times on various plates, we noticed that there
were distinct hazes around the regions of growth that looked similar to twitching zones. P.
aeruginosa is equipped with the ability to swim via flagella and twitching via type IV pili.
Because mucoid strains aren’t supposed to be as motile as nonmucoid strains, we decided to
screen the mtpX mutants in various motility assays.
Swimming Assay Shows Increase in Mucoid Background ∆mtpX
The swimming assay was performed on LB plates with 0.3% agar. After incubating for 48
hours at 30°C, the zones of swimming were measured. Because the medium is not as thick,
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bacteria use their flagella to “swim” through the medium. P. aeruginosa’s ability to swim varies
upon the strain. Here we looked at the mutants in both backgrounds (Figure 15). PAO1 and its
mtpX mutant showed no real difference in swimming. The mucA22 strain is not supposed to
express flagella; instead it is supposed to be more stationary. However, the mucA22ΔmtpX
mutant swam more than mucA22 and PAO1. At the time we did not know why this occurred or
how it may relate to RsmA levels in the cell. We decided to look at twitching in these mutants as
well.

Figure 15. Swimming Assay of mtpX mutants and parent strains. mucA22∆mtpX was the only
significant result in the swimming assay. Zones of growth were measured in centimeters. Two
stars represent a p<0.01.
Twitching Assay Shows Increase in Mucoid Background While Decreased in Nonmucoid
Background
The twitching assay looks at the ability of bacteria to propel themselves through a thicker
media, 1.5% agar media. We showed that the inner membrane protein MtpX has some effect on
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twitching in both backgrounds (Figure 16A). Zones are measured after the agar is removed and
have been stained with crystal violet ( igure 16B). PA 1ΔmtpX showed a decrease in twitching
ability, almost to the level of mucA22, which is not able to twitch. However, similarly to the
swimming assay the mucA22ΔmtpX strain was able to outperform PAO1 in twitching zones and
was drastically different from mucA22.

igure 16. Twitching Assay showing the effects of ΔmtpX on type IV pili in both mucoid and
nonmucoid backgrounds. A. Measurements in millimeters of twitching zones. B. Images of
crystal violet stained twitching zones under their respective strain.
Transmission Electron Microscopy (TEM) of ΔmtpX Mutants
Because the motility assays were presenting such interesting results, we set out to visualize
the cell surface via TEM. We found that 2% UA provided the best results in visualizing the cells
with the TEM when compared to 2% phosphotungstic acid (PTA). The most alluring data, the
mtpX mutants, show the presence of flagella on their cells. PAO1 (Figure 17A) is our wildtype
strain that can express either flagellum or type IV pili. We have shown through the motility assay
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that both conditions are possible depending on the type of media used. n the PA 1ΔmtpX cell
(Figure 17C), we see a single polar flagellum. This image explains the mutant strains ability to
swim but not twitch. In the mucoid background, we see mucA22 (Figure 17B) secreting
exopolysaccharide and the cell also has cellular appendages. However, the

Figure 17. Transmission Electron Microscopy of PAO1(A), mucA22(B), PA 1ΔmtpX(C), and
mucA22ΔmtpX(D). Black arrows designate single polar flagellum.
mucA22ΔmtpX cell (Figure 17D) shows small amounts of exopolysaccharide and, like the
PA 1ΔmtpX cell, a single flagellum. This explains our swimming results.
Siderophore Production Increases in Mucoid Background ∆mtpX
Mutant strains growing on both LB and PIA plates were producing an unusual amount of
yellow-green pigment extending from areas of growth. Under the presence of ultraviolet(UV)
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light, the green pigment fluoresced, which is a trademark of pyoverdine, an iron-binding
compound produced by P. aeruginosa. We made CAS plates in order observe the production of
pyoverdine. When iron is sequestered by siderophores, the iron-dye complex of the plate turns
from blue to orange when pyoverdine is produced (21). Here we measured the orange zones to
see if the mtpX mutants were producing more pyoverdine than PAO1 and mucA22 (Figure 18A).
We also exposed the patched strain to UV light to confirm we were actually seeing pyoverdine
(Figure 18B). mucA22ΔmtpX showed a significant increase in siderophore production when
compared to mucA22 and was statistically significant in this experiment.

Figure 18. Measured zones of pyoverdine in millimeters (A). Plates exposed to UV light (B)
under their respective strain.
Biofilm Assay Shows Decrease in Nonmucoid Background ΔmtpX Mutant
P. aeruginosa is well known for its production of biofilm by secreting exopolysaccharide
on both biotic and abiotic surfaces. Our mucoid strain mucA22 produces a very thick biofilm of
alginate. We set out to see if our mtpX mutants have decreased production of biofilm. When P.
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aeruginosa is expressing flagella, it is not as likely to be producing biofilm. We also saw a
drastic phenotypic change in the mucA22∆mtpX strain, which we assumed affected biofilm. We
performed a microtiter biofilm assay (31) and determined the amount of biofilm that adheres to
the polystyrene sides using crystal violet and spectrophotometry (Figure 19A). We also looked at
patch plating the strains on to Congo Red media (Appendix) (Figure 19B) for any difference in
appearance on this media. The Congo Red dye will bind exopolysaccharide secreted by cells,
with red or purple strains expressing more biofilm (22).

Figure 19. Microtiter Biofilm Assay of ∆mtpX mutants, measured at O.D. 620nm(A).
PA 1∆mtpX was the only strain to show any difference in biofilm production. One star
represents a p<0.05. Strains patch plated on Congo Red media (B) show no drastic color
appearance.
The PA 1∆mtpX strain exhibited a decrease in biofilm production, while the mucA∆mtpX
showed no difference in biofilm production.
Alginate Assay Shows Decrease in Mucoid Background ΔmtpX
The biofilm assay did not give us the results we expected, so we decided to perform an
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alginate assay because of the visual appearance of the mucA∆mtpX. The mucA∆mtpX showed a
significant decrease in alginate production (Figure 20). These results confirmed that MtpX is
required for alginate production. The amount of alginate was quantified via a standard curve.
This experiment was performed in triplicate. As indicated in Figure 20, the mucA22ΔmtpX
mutant had an almost 2000-fold reduction in alginate. This is the first description of this
transporter playing a role in alginate production.

igure 20. Quantification of alginate produced by ∆mtpX mutants (A) and images of strains on
PIA plates (B). mucA22∆mtpX showed a significant decrease in alginate production. Two stars
represent a p<0.01.
Reverse Transcriptase PCR on mtpX/PA1627 Operon
Besides phenotypically analyzing the ∆mtpX mutants, we wanted to characterize the mtpX
messenger RNA. Bioinformatic data suggest that mtpX is in an operon with the upstream gene,
PA1627, a probable transcriptional regulator. Using gene sequence from pseudomonas.com, we
designed primers to produce cDNA for the mRNA containing both mtpX and PA1627 (41).
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Forward primers were located at the start of the intergenic space between PA1628 and PA1627,
the start of PA1627, and the middle of PA1627. Our results (Figure 21) showed that PA1627 and
mtpX were indeed transcribed in the same message. However, the significance of these results
has not been elucidated.

Figure 21. RT-PCR of PA1627/mtpX operon to confirm these 2 genes were in an operon.
Genomic DNA was used as a positive control. RNA without reverse transcriptase was used as a
negative control to ensure there was no genomic DNA contamination. Amplified products were
run on a 1% agarose gel. Location of primers on a genomic model is shown below the gel.
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CHAPTER 4
DISCUSSION
P. aeruginosa is a virulent opportunistic pathogen notorious for causing complications in
immunocompromised individuals and nosocomial infections. An understanding of how P.
aeruginosa uses its virulence factors to cause infections could lead to better chemotherapeutic
treatment of this pathogen. By studying the global regulator RsmA, we have not only learned
more about the network of virulence factors it controls but also the regulators of rsmA’s
expression.
rsmA Regulators
The screen to identify rsmA regulators has increased our knowledge of how this important
posttranscriptional regulatory system is controlled. pilW was interrupted in the mucoid strain
mucA22, which is thought to not express type IV pili(4). However, when the transposon
interrupted the minor pilin gene, we saw a significant decrease in rsmA expression. Because pilW
is in an operon with 6 other pilin genes, we made a knockout mutant of pilW to confirm our
transposon results. We found PilW does affect rsmA expression in this background (data not
shown) and have set out further to study the effects it has on RsmA. Another interesting gene to
study will be the probable transcriptional regulator PA2028. We still have to knockout this gene
and to determine its effects on RsmA’s antagonists, RsmY and RsmZ. Lastly, there is mtpX the
probable major facilitator superfamily transporter. MtpX shows weak homology to CynX, a
cyanate permease in E. coli with 33% identical residues and 54% similar residues (15,16,32). In
P. aeruginosa there are 2 other genes that are more homologous to CynX. Since only a few parts
of Mtp ’s cellular function have been elucidated ( igure 22) in both mucoid and nonmucoid
backgrounds of P. aeruginosa, we are looking to further study this inner membrane transporter.
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We have shown that there is a definitive relationship between the expression of rsmA and
Mtp . After confirming the transposon mutant with β-galactosidase assays of a ΔmtpX mutant,
we discovered divergent results in our 2 backgrounds (Figure 20). In the mucoid background, we
saw a slight decrease in the 2 mRNAs of rsmA via RNase Protection Assay.

Figure 22. Mechanism proposal of MtpX representing the mucoid strains (A) and nonmucoid
strains (B). Arrows denote an up-regulation while squares represent down-regulation of genes.
ur Western Blot analysis also confirmed the loss of RsmA in the ΔmtpX mutant. We have
seen through β-galactosidase assays that RsmY and RsmZ greatly increase in the mucoid
background. This may explain the loss of RsmA from the Western Blot in the mucA22 ΔmtpX
strain as the decreased levels are bound by RsmA’s antagonists. We can pursue this answer by
using a rsmY- lacZ and rsmZ-lacZ fusion and confirming the results with RNAse Protection
Assays. We can also look at RsmA with a Western Blot in mucA22ΔrsmYΔrsmZ and
mucA22ΔrsmYΔrsmZΔmtpX mutants with HA-tagged RsmA. If RsmY and RsmZ are factoring
into the levels of RsmA in the ΔmtpX mutant, either of these experiments would explain the
results. Contrarily, MtpX may regulate RsmY and RsmZ. Because we saw a disappearance of
RsmA levels via the Western blot analysis in the mucoid background, MtpX could down regulate
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the expression of rsmY or rsmZ. By looking into rsmY and rsmZ expression in the mucoid
background, increases in expression of these 2 small RNA may explain our rsmA results. We can
also overexpress rsmY and rsmZ in the nonmucoid background, to see if the results are opposite
and RsmA levels decrease (35). In the RNase Protection Assay and Western blot analysis, we
saw contrasting results between nonmucoid and mucoid backgrounds.
For the case of the nonmucoid background, we saw a marked increase in the rsmA mRNA
with AlgU promoter. We can confirm that MtpX affects AlgU by knocking out AlgU and
performing another RNase protection assay in this double mutant with the rsmA probe, as well as
looking examining RsmA levels in an algU mutant strain. After completing this series of
experiment, we may be able to better understand the role MtpX shares with rsmA expression.
Characterizing MtpX
Seeing the transposon mutant revert from the mucoid mucA22 rsmA-lacZ strain to a
nonmucoid variant was concerning at first. After repeatedly making the knockout mutant in
mucA22 and also our 2 mucoid CF clinical isolates, FRD1 and 2192, it was clear that the MtpX
transporter plays an important role in alginate production. This may provide a new
chemotherapeutic target that may help eradicate P. aeruginosa infections in cystic fibrosis
patients (7). The most interesting effect of knocking out the mtpX gene, besides loss of alginate
production, is the appearance of flagella on the P. aeruginosa cells. Dispersion mechanisms are
en vogue currently in Pseudomonas pathogenesis research and MtpX may play a role in biofilm
dispersion given that the mucA22ΔmtpX demonstrated increased swimming compared to the
mucA22 parent. Even though our biofilm assays did not detect a difference in biofilm formation
using the microtiter plate assay, we did not specifically examine biofilm dispersal. This will be
the subject of further investigation. Additionally, the overespression of pyoverdine suggests that
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the mucA22ΔmtpX mutant may have a problem acquiring iron or in overproducing exzymes
requiring iron. Further investigation of this mutant will provide important insights into the
pathogenic mechanisms used by P. aeruginosa.
Further investigations analyzing the transcriptional regulation of the mtpX genomic region
are underway. This will include mapping the transcriptional start site of PA1627 by primer
extension. In doing so, we will be able to possibly identify the promoter of this operon. It is also
in our interest to make a knockout mutant of PA1627 in both mucoid and nonmucoid
backgrounds and look at the effects on rsmA expression. Because PA1627 is a transcriptional
regulator, it could possibly auto regulate the mtpX-PA1627 operon. Additional studies into the
regulation of this system are needed to identify new possible drug targets. Isolating the MtpX
protein and clarifying the substance it transports will also be crucial to closing the chapter on this
regulator of rsmA expression. Although there are still more questions to answer, we feel that
Mtp may prove to be an important resource not only in RsmA’s cellular role but also the
pathogenicity of Pseudomonas aeruginosa.
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APPENDICES
Appendix A: Media
PIA (1 Liter)
935 ml ddH2O
20 ml Glycerol
bring to boil
Add:
20g Peptone
10g Potassium Sulfate
13.6g Agar
1.4g Magnesium Chloride
25mg Irgasan(irg)
Autoclave
Antibiotic concentrations:
150 μg/ml gentamicin
80 μg/ml -gal
LB (1 Liter)
940 ml ddH2O
15g Agar
10g NaCl
5g Yeast Extract
10g Tryptone
Autoclave
Antibiotic concentrations:
15 μg/ml gentamicin
10 μg/ml tetracycline
100 μg/ml ampicillin
50 μg/ml kanamycin
LB no NaCL tet50 irg25 (1 Liter)
same as LB, just no salt added
25 mg Irgasan
Autoclave
50 μg/ml tetracycline
1% agarose gel (for 2 gels)
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0.5 g Agarose
5 ml 10X TBE
45 ml ddH2O
Microwave for 1 minute
Add 2.7 μl Ethidium Bromide when container is warm to touch
M9 salts
10X M9 salts (500 ml)
30g Na2HPO4
15g KH2PO4
2.5g NaCl
5g NH4Cl
pH to 7.4
For 100ml of broth:
10ml 10X M9 salts
0.2 ml 1M MgSO4
0.1 ml 0.1M CaCl2
0.1 ml 1M thiamine HCl
Add 1% carbon source of interest.
VBMM
500 ml 10X VBMM stock
400 ml ddH2O
15g Trisodium Citrate
10g Citric Acid
50g K2HPO4
17.5g NaNH4PO4 · 4H2O
pH to 7 and autoclave
plates (500ml):
400 ml ddH2O
7.5g Agar
autoclave and allow to cool to 50°C
50 ml 10X VBMM
500 μl 1M Magnesium Sulfate
50 μl 1M Calcium Chloride
Antibiotics:
300 μg/ml Carbenicillin
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M63 minimal media broth(31)
5X M63 stock: (1 Liter)
15g KH2PO4
35g K2HPO4
10g (NH4)2SO4 ddH2O to 1L
Broth final concentrations:
1X M63
1% Glucose
1mM MgSO4
1% Glycerol
0.5% Casamino acids
0.4% Arginine
sterile ddH2O to final volume desired
Congo Red(22)
5g Tryptic Soy Broth
6.7g Agar
460 ml ddH2O
Autoclave and cool to 50ºC
Congo Red 40μg/ml Coomassie Brilliant Blue 20μg/ml
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Appendix B: Buffers
10X TNE
830 ml ddH2O
12.1g Tris Base
3.7g EDTA
116.8g NaCl
1X TBS-T
10X TBS:
12.1g Tris base
43.8g NaCl
ddH2O to 500 ml
1X TBST:
100 ml 10X TBS
500 μl of Tween 20
ddH2O to 1 L
10X TE
108g Tris Base
55g EDTA
900 mL ddH2O
Z Buffer
900 ml ddH2O
16.1g Na2HPO4 · 7H2O
5.5g NaH2PO4 · H2O
0.75g KCl
0.246g MgSO4 · 7H2O
pH to 7 and autoclave
Add 2.7 μl/ml of β-mercaptoethanol when ready to use
10X TBE
108g Tris Base
55g Boric Acid
40 ml 0.5M EDTA
900 ml ddH2O
TEST Buffer
500 μl 1M Tris
120 μl 0.5M EDTA
1.5 ml 50% sucrose
500 μ 10% Triton -100
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4x SDS Loading Buffer
4.4 ml 0.5M Tris HCl pH6.8
4.4 ml Glycerol
2.2 ml 20% SDS
0.5 ml 1% Bromophenol Blue
0.5 ml β-mercaptoethanol
Store at -20ºC
10X Glycine Running Buffer
30.3g Tris Base
144.1g Glycine
10g SDS
ddH2O to 1L
1.5M Tris HCl pH 8.8
27.23g Tris base
80ml ddH2O
adjust pH to 8.8 with 6N HCl
ddH2O to 150 ml
0.5M Tris HCl pH6.8
6.1g Tris base
80ml ddH2O
pH to 6.8 with 6N HCl
ddH2O to 100 ml
Towbin Buffer
10X Towbin Buffer:
30.3g Tris base
144g Glycine
ddH2O to 1 L
1X Towbin buffer for Electroblotting:
10 ml 10X Towbin buffer
20 ml Methanol
70 ml ddH2O
Blocking Buffer
2.5g Skim Milk powder
5 ml TBS-T buffer
45 ml ddH2O
1° antibody Wash
2.5g Skim Milk powder
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5 ml TBS-T buffer
45 ml ddH2O
2.5 μl of HA-tag antibody
Washing Buffer
5 ml TBS-T buffer
45 ml ddH2O
2° antibody Wash
2.5g Skim Milk powder
5 ml TBS-T buffer
45 ml ddH2O
2.5 μl of anti-goat/anti-mouse antibody
Sulfuric Acid/Borate Solution
975 ml Sulfuric Acid
25 ml Borate Solution
Borate Solution
10.09g KOH in 45 ml of ddH2O
24.74g Boric Acid
ddH2O to 100 ml
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Appendix C: Primers & Plasmids
Primers
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Plasmids
plasmid
pBT20
pMX19
pRHA18
pMX18
mini-CTX-AlacZ
pRK2013
pFLP2

Relevant Characteristics
transposon, GmR
∆mtp , AmpR
rsmA-HA, GmR
∆mtp , TetR
rsmA-lacZ, TetR
used for triparental mating, KanR
used for removing mini-CTX, AmpR
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Source or reference
(33)
this study
this study
this study
this study
(11)
(39)
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